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Individuals infected with human immunodeﬁciency virus (HIV) frequently demonstrate metabolic syndrome (MS) associated
with increased incidence of cardiovascular disorders. Characteristics of HIV infection, such as immunodeﬁciency, viral load, and
duration of the disease, in addition to the highly active antiretroviral therapy (HAART) have been suggested to induce MS in
these patients. It is well documented that MS involves a number of traditional cardiovascular risk factors, like glucose, lipids, and
arterial blood pressure abnormalities, leading to extensive atherogenic arterial wall changes. Nevertheless, the above traditional
cardiovascular risk factors merely explain the exacerbated cardiovascular risk in MS. Nowadays, the adipose-tissue derivatives,
known as adipokines, have been suggested to contribute to chronic inﬂammation and the MS-related cardiovascular disease.
In view of a novel understanding on how adipokines aﬀect the pathogenesis of HIV/HAART-related MS and cardiovascular
complications, this paper focuses on the interaction of the metabolic pathways and the potential cardiovascular consequences.
Based on the current literature, we suggest adipokines to have a role in the pathogenesis of the HIV/HAART-related MS. It is
crucial to understand the pathophysiology of the HIV/HAART-related MS and apply therapeutic strategies in order to reduce
cardiovascular risk in HIV patients.
1.Introduction
Treatment with highly active antiretroviral therapy
(HAART) in patients infected with human immunodeﬁ-
ciency virus (HIV) has been documented to signiﬁcantly in-
crease life expectancy [1]. However, adverse metabolic eﬀects
like dyslipidemia, increased blood pressure, and in-sulin
resistance have been attributed to HAART [2, 3]. There-
fore, the use of HAART raises concerns regarding metabolic
disorders and cardiovascular risk in HIV-infected patients
who now present an extended life expectancy. An increase of
approximately 26% of the risk for myocardial infarction has
been reported in patients on HAART [4]. The detrimental
eﬀect of HAART on the arterial wall properties [5–8]h a s
been proposed as an underlying mechanism, while it has
been documented that HIV infection per se may promote
atherosclerosis through immunodeﬁciency, chronic inﬂam-
mation progress, viral load, and endothelial cell dysfunction,
and either directly or indirectly via metabolic risk factors
[9–13]. The exact pathophysiological events underlying the
development of metabolic changes in HIV-infected patients
are still under investigation. Several studies have identiﬁed
speciﬁc defects in adipocyte function as main drivers in
the pathogenesis of some of the metabolic changes in these
patients. The list of adipocyte-secreted cytokines, known
as adipokines, has been continuously expanded to include
biomolecules, such as leptin, adiponectin, resistin, visfatin,
apelin, acylation stimulating protein, omentin, and vaspin.
In addition to this, TNF-α, adipose-derived interleukins, and
acute-phaseproteinshavebeenalsoconsideredasadipokines
by some researchers [14]. We should mention that the cur-
rent terminology refers to a cytokine as an immunomodu-
lating agent. Taking this into account, adiponectin, leptin,
and resistin are not appropriately considered as adipokines,
since they do not act on the immune system. Nevertheless,
these peptides are still referred to as adipokines in the2 Experimental Diabetes Research
Table 1: The main diﬀerences between the pathogenesis of MS in
HIV-infected patients and other patients.
HIV-infected patients Non-HIV-infected patients
(A)
HAART-induced
dyslipidemia,
hypertriglyceridemia, HDL
reduction, especially if PI
used
Fat abnormal metabolism
leading to
hypertriglyceridemia and
dyslipidemia
(B)
HAART-induced leptin
deﬁciency and
hypoadiponectinemia
leading to insulin resistance
Hypoadiponectinemia
leading to insulin resistance
and abnormal glucose
metabolism
(C)
HIV-associated
“lipodystrophy”
syndrome—body fat
abnormalities—fat
accumulation around the
neck, dorsocervical region as
“buﬀalo hump,” abdomen,
and trunk
Waist circumference
enlargement due to
abdominal fat accumulation
literature; however, they could be more accurately put into
the larger, growing list of adipose-tissue-derived hormones.
The role of those adipose-tissue-secreted hormones in the
pathophysiology of HIV-/HAART-related metabolic syn-
drome (MS) in HIV-infected patients is still the subject of
intense research. Therefore, we decided to review published
data regarding the emerging role of adipokines in the in-
creased cardiovascular risk in HIV-infected patients related
to the HIV/HAART-associated MS. The main diﬀerences
between the pathogenesis of MS in HIV-infected patients
and other patients are summarized in Table 1.
2.Bod yF atandW aistC ir cumf e r e nc e
AbnormalitiesinHIV-InfectedPatients
The prevalence of the HIV-associated “lipodystrophy” syn-
drome according to previous studies approaches 80% of
patients receiving HAART [15], while other studies report
only a prevalence of 17% [16]. Signiﬁcant diﬀerences in
“lipodystrophy” rates exist when comparing patients with
or without HAART. In one of these studies the prevalence
of any body change was 62% in protease inhibitor (PI)-
experienced patients, 33% in PI-naive patients and 21% in
antiretroviral-naive patients [17]. There seems to be a lower
prevalence of morphological body shape and fat redistribu-
tion changes in HIV-infected children, while an increase in
serum adipokine levels has been additionally described [18].
According to the European Paediatric Lipodystrophy Group,
approximately a quarter of children and adolescents show
signs of lipodystrophy, similar to those described in adults
[19].
Lipoatrophy typically includes decreased subcutaneous
fat in the upper or lower extremities with prominent veins,
loss of buttock subcutaneous fat, and facial atrophy [20].
The fat wasting should be diﬀerentiated from other wasting
conditions associated with HIV infection, including the
AIDS-wasting syndrome, malnutrition, cachexia, adrenal
insuﬃciency, and severe chronic infections.
Lipodystrophy is characterized by lipoatrophy/fat loss,
lipohypertrophy/fat accumulation, or both [20]. Fat accu-
mulation can be seen around the neck, the dorsocervical
region as “buﬀalo hump,” the abdomen, and the trunk or as
subcutaneous fat deposits, that is, lipomas, particularly in
the dorsocervical area. These ﬁndings can be either sym-
metric or asymmetric. Breast enlargement has also been
observed.
3.DyslipidemiaandInsulinResistancein
HIV-InfectedPatients
The association of dyslipidemia with many antiretroviral
regimens and especially PIs has been well established [21].
The eﬀect on total cholesterol levels appears to be regimen
dependent as shown in the Swiss HIV-1 Cohort Study [22].
Potential mechanisms for PI-associated dyslipidemia include
(a) inhibition of sterol regulatory element-binding protein-
1 (SREBP-1) activation in the liver and/or adipocytes along
with the protease-mediated breakdown of apolipoprotein-
B[ 23], (b) direct enhancement of the formation of very-
low-density lipoproteins (VLDLs) [24] and the reduction
of lipoprotein lipase activity [25], and (c) changes in the
mobilizationoflipidstores[26].Nevertheless,lipiddisorders
can also occur during therapies not including PIs [27, 28].
Insulin resistance is also a signiﬁcant metabolic side eﬀect
associated with HAART. PIs aﬀect insulin sensitivity through
various mechanisms such as IRS-1 phosphorylation and
subsequent glucose uptake from adipocytes [29]. Lipodys-
trophy may also result in B-cell dysfunction [30] and is
associated with impaired feedback of insulin on B-cells
[31]. On the other hand, HIV-1 infection itself may be
independently linked to the attenuation of insulin sensi-
tivity. The HIV-1 accessory protein Vpr induces transcrip-
tion of glucocorticoid-responsive promoters, in vitro,t h u s
increasing sensitivity to glucocorticoids [32]. It also attenu-
ates peroxisome-proliferator-activated receptor-γ (PPAR-γ)
activity [33] and interferes with the suppressive eﬀects of
insulin on forehead transcription factors [34]. Therefore, it
contributes to the tissue-selective insulin resistance. The end
result of all the described factors is the attenuation of insulin
sensitivity.
4. Parametersof HIV-/HAART-Induced
Metabolic Syndrome and
CardiovascularDisorders
Concerning arterial stiﬀness, expressed by pulse wave veloc-
ity (PWV), and markers of metabolic proﬁle, we recently
compared HIV-infected patients age- and sex-matched
individuals with either with hypertension or without any
chronic disease [35]. In that study, HIV-infected patients
had higher PWV levels than healthy controls, but lower
than hypertensive patients. Notably, patients on HAART
had similar PWV to hypertensive patients. In multivariate
analysis, the independent determinants of increased arterialExperimental Diabetes Research 3
stiﬀness were HAART duration and MS parameters, like
serum lipids and blood pressure.
In our previously published study, we performed a com-
parative evaluation of endothelial dysfunction between HIV-
positive individuals and age- and sex-matched controls with
similar risk factors and a group of patients with established
coronary artery disease (CAD). HIV-infected patients pre-
sented endothelial dysfunction to a similar extent as patients
with CAD. Moreover, HIV-infected patients taking PIs had
higher blood pressure, cholesterol, and triglycerides than
those not taking PIs. Importantly, endothelial dysfunction
was associated with elevated serum triglycerides. Therefore,
we concluded that HAART-induced hypertriglyceridemia
might have been a plausible mechanism explaining endothe-
lial dysfunction in HIV-infected individuals. In the same
study, we found an increased carotid intima media thickness
(IMT), an index of subclinical carotid atherosclerosis, in
HIV-infected patients. Most importantly, carotid IMT levels
were equivalent in HIV-infected and CAD groups. So, we
suggested that subclinical carotid atherosclerosis was closely
related to PI-related changes of metabolic parameters in
HIV-infected patients.
Current recommendations by the National Cholesterol
Education Program for HIV-infected persons focus on LDL-
C levels, as the primary target of the lipid-lowering therapy.
The LDL cholesterol goal has been set <160mg/dL for
persons with 0-1 cardiovascular risk factors, <130mg/dL for
persons with multiple (2+) risk factors, and <100mg/dL for
persons with established coronary heart disease (CHD) or
CHD risk equivalents. After lifestyle modiﬁcations, statins
should be used to lower LDL-C levels. Therapy with ﬁbrates
is recommended to lower triglycerides levels. However,
omega-3 fatty acids can be eﬀective means of triglycerides
lowering as well, particularly in patients with markedly
elevated triglycerides levels. The eﬃcacy of statins in HIV-
infected persons appears to be lower than expected, although
adherence to statins therapy has not been well assessed.
Statins combining high potency and minor interactions with
antiretroviral therapy (pravastatin, ﬂuvastatin, atorvastatin,
and rosuvastatin) should be preferred as the initial therapy,
though comparative studies in HIV-infected persons are
scarce.
Adequate choice and dosing of lipid-lowering drugs,
given as single agents or in combination therapy, and care
for drug compliance in HIV-infected patients at moderate
or high cardiovascular risk should help maximize their long-
term health.
5.HIV-/HAART-InducedMetabolicSyndrome:
The Role of Adipokines
Visceral adipose tissue (VAT) is the predominant adipose
tissue compartment responsible for the production of adipo-
kines. A growing body of evidence supports the emerging
role of adipokines in metabolic homeostasis and athero-
sclerosis. In this paper, we have reviewed the recent progress
regarding the role of adipokines in the HIV/HAART-
induced MS and cardiovascular disease (CVD). A better
understanding of the molecular mechanisms will lead to
the discovery of new drugs and reduce the incidence of
lipodystrophy and related metabolic complications in HIV-
infected patients receiving HAART.
5.1. Leptin. Leptin, which was the ﬁrst adipokine identiﬁed,
inﬂuences food intake through direct eﬀects on the hypotha-
lamus [36]. This adipocyte-derived hormone has actions in
the brain (e.g., hypothalamus, cortex, and limbic areas) and
in a number of peripheral tissues as well as cells of the
pancreas, liver, and immune system. The central actions of
leptin include energy and glucose homeostasis, reproductive
functions, and immunity [37, 38]. The relationship between
adiposity and leptin levels appears similar to controls and
HIV infected but untreated patients [39]. On the other hand,
severe lipodystrophy syndromes are characterized by loss
of subcutaneous adipose tissue and a relative deﬁciency of
leptin [40]. The eﬀect of HAART on leptin levels is subject
of controversy. In few studies, HAART administration had
beenassociatedwithlipodystrophyandhypoleptinemia[41],
while numerous studies had predominantly demonstrated
noeﬀectofHAARTonleptinconcentrations[42].Theabove
discrepancy was mainly attributed to the diﬀerential eﬀects
of HAART on fat-massdistribution and not directly to leptin
perse[43].Indeed,HAARTwithoutfat-massre-distribution
did not inﬂuence leptin levels [44]. Moreover, there is a weak
correlation of leptin with insulin sensitivity in HIV-infected
population [45].
Accumulating data support the proinﬂammatory and
proatherogenic properties of leptin in either noninfected or
HIV-infectedpatients[46,47].Althoughthereisnoprospec-
tive study evaluating the association of leptin with long-
term cardiovascular events in HIV infected patients, the high
levels of leptin in that population apparently increases the
inﬂammatory milieu and perhaps the total cardiovascular
risk. Future studies will elucidate the role of leptin in CVD
progression in HIV-infected patients.
5.2. Adiponectin. Adiponectin, a well-studied adipokine, is
secreted by fatty cells and is widely regarded to exert a coun-
terregulatory role in atherogenesis, by its antioxidant, anti-
inﬂammatory, antithrombotic, and direct anti-atheroscle-
rotic properties [48]. Adiponectin expression is suppressed
in patients with obesity and type 2 diabetes, showing an
inverse relationship with insulin resistance and visceral adi-
posity[49].Treatment-na¨ ıve,HIV-1-positive patientsappear
with suppressed adiponectin levels [50]. In previous studies,
circulating adiponectin levels were suppressed in patients
with chronic HIV infection and fat redistribution, but the
underlying mechanisms remain obscure [51, 52]. Moreover,
patients treated with HAART, especially those with lipodys-
trophy, showed gradual downregulation in adiponectin
serum levels [53]. Notably, in the latter subgroup of patients,
the HAART-induced hypoadiponectinemia was associated
with accelerated cardiovascular impairment [54]. Taken all
together, the suppression of adiponectin levels in HIV-
infected patients under HAART may deteriorate numerous
metabolic parameters (e.g., insulin resistance, lipid proﬁle,
etc.) leading to detrimental cardiovascular events.4 Experimental Diabetes Research
5.3. Resistin. Despite the quite promising data from rodent
studies, human data did not consistently conﬁrm the associ-
ation of resistin with insulin resistance, diabetes, and obesity
[55]. Contrary to the aforementioned ﬁndings, elevated
resistinlevelshavebeenfoundinHIV-infectedpatientscom-
pared to uninfected individuals. That diﬀerence was ascribed
to HAART-related metabolic changes [56, 57]. Perhaps,
HIV/HAART-related MS alters the regulatory mechanisms
of resistin, but this hypothesis requires further investigation.
On the other hand, the predominant sources of human
resistin are macrophages and mononuclear leukocytes, and
to a lesser extent, adipocytes [58]. Conditions of low-grade
systemic inﬂammation, such as diabetes and atherosclerosis,
may induce macrophage expression of resistin and increase
circulating levels, independently of metabolic changes. The
latter notion is also supported by the previously reported
contributory role of resistin to pathologic processes, like
inﬂammation, endothelial dysfunction, thrombosis, and
smooth muscle cell dysfunction, leading to CVD [59].
Unambiguously, future studies will shed more light on the
interplay between resistin and HIV/HAART-related MS and
CVD.
5.4.Visfatin. Visfatin, alsoknown as nicotinamide phospho-
ribosyltransferase (NAMPT), functions as a growth factor
for early B cells within the immune system [60]. Although
visfatin is expressed and regulated by the adipose tissue,
its relationship with adiposity-related insulin resistance is
controversial [61, 62]. Regarding the impact of HAART on
visfatin, a single study demonstrated signiﬁcantly increased
serum visfatin levels after HAART initiation, along with
insulin resistance augmentation, and without concomitant
changes in fat mass [63]. Thus, the ﬂuctuations of insulin
resistance and glucose homeostasis in HIV-positive patients
may explain the regulation of visfatin.
Importantly, patients with stable coronary and carotid
diseaseappearwithhighcirculatinglevelsofvisfatin[64,65],
while macrophages derived from human unstable carotid
and coronary plaques increasingly express visfatin [66].
Future studies clarifying the involvement of proinﬂamma-
tory visfatin in the HIV/HAART-associated MS may better
deﬁne the cardiovascular risk.
5.5. Apelin. Apelin, an adipocyte-secreted factor, has been
recently identiﬁed as a contributor to glucose homeostasis
and insulin resistance [67]. Abundant expression of apelin
and its receptor, APJ, has been detected in endothelial cells
from large arteries and coronary blood vessels and in the
heart [68]. Moreover, previous trials have suggested apelin
as a potent regulator of cardiovascular function [69]. We and
other investigators have recently documented the inverse
relationship between circulating apelin levels and CHD
[70, 71].
The interplay between apelin with HIV infection and
initially reported by Zou et al. who described the inhibition
of HIV-1 and HIV-2 entrance in CHO and NP-2 cells
expressing CD4 and its receptor after preincubation with
apelin [72]. Moreover, apelinreceptor has been shown in
vitro to act as HIV-1 coreceptor [73]. Taken together, more
functional studies are required to determine the precise role
ofapelin/APJincardiovascularregulation, insulinresistance,
and the susceptibility to HIV infection. This information
would help to evaluate its potential as a future drug target.
5.6. Vaspin. A novel adipokine, vaspin, has been recently
designated as a mediator of obesity, insulin resistance, and
type 2 diabetes [74]. Both animal and clinical studies suggest
that elevated vaspin levels in serum and adipose tissue may
be a compensatory response to elevated insulin resistance,
secondary to metabolic complications [75]. Extremely
limited data implicate the association of low serum vaspin
levels with atherosclerosis development and progression
[64, 76]. Although vaspin exerts insulin-sensitizing and
atheroprotective actions, its relationship with cardiovascular
complications in HIV/HAART-related MS has not been
investigated.
6. Conclusions
Adipokines appear to have a leading role in the pathogenesis
of the HIV/HAART-related MS [77]. Leptin deﬁciency and
hypoadiponectinemia, for example, correlate with insulin
resistance and body fat abnormalities. These disorders aﬀect
the cardiovascular health of HIV patients through the
amelioration of atherosclerosis and endothelial dysfunction.
Furthermore, novel adipokines, such as visfatin, apelin, and
vaspin, have emerged as potential mediators of the interplay
between MS and atherosclerosis in HIV-infected patients. It
is of great interest to study the pathological mechanism of
the HIV/HAART-related MS and its cardiovascular compli-
cations and try to apply therapeutic strategies in order to
reduce cardiovascular risk in HIV patients.
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